ArticleFrontiers in pharmacology2026
Delirium associated with moxifloxacinin a patient with toxic epidermal necrolysis due to methazolamide: a case report.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Toxic epidermal necrolysis (TEN) is a potentially life-threatening adverse drug reaction characterized by extensive epidermal detachment and mucosal erosions. While delirium is a known complication in critically ill patients, its association with TEN remains poorly characterized. Case: We report a case of moxifloxacin-induced delirium with psychotic features in a patient who developed TEN secondary to methazolamide following orbital trauma. Physical examination revealed erythematous plaques with multiple flaccid bullae and widespread skin sloughing involving more than 40% of the total body surface area. The SCORTEN score was calculated as 2, corresponding to a predicted mortality rate of 12.1%. The patient was treated with intravenous immunoglobulin, systemic glucocorticosteroids, and supportive care. During hospitalization, she developed delirium attributable to moxifloxacin administration, which resolved promptly upon drug discontinuation. Conclusion: Delirium in critically ill dermatological conditions such as TEN is often multifactorial in origin. It may arise as a direct complication of severe systemic illness or as an adverse effect of necessary pharmacotherapy, with fluoroquinolones representing a well-recognized precipitant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.